Company News: Page (1) of 1 - 08/10/17 Email this story to a friend. email article Print this page (Article printing at page facebook

Syndax Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Clinical and Business Update

- PD-1 Refractory Melanoma Cohort of ENCORE 601 Completes Enrollment -- First Patient Dosed in ENCORE 601 Colorectal Cancer Cohort --Company to Host Conference Call Today at 4:30 p.m. ET- (August 10, 2017)
This article is no longer available,but here are some related topics.

Page: 1

Related Keywords:Pro AV,Management,Presentors,Business,Law,Business Issues,Internet Media,Presentation,Events, webcast,USA, Inc.,Science,Medical,Biology,Cancer,Business,Other,


Our Privacy Policy --- @ Copyright, 2015 Digital Media Online, All Rights Reserved